Acitretin
Brand names: Neotigason
Acitretin is an oral systemic retinoid used for severe, treatment-resistant psoriasis and certain disorders of keratinisation.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
As a vitamin A derivative it modulates epidermal cell proliferation and differentiation, normalising the abnormal keratinisation and hyperproliferation seen in psoriasis.
Prescribing in practice
- It is a potent teratogen and is contraindicated in pregnancy, requiring reliable contraception during treatment and for an extended period afterwards under a pregnancy prevention approach.
- It can cause hepatotoxicity and marked elevations in serum lipids, so liver function and lipids must be assessed before and during treatment.
- Alcohol should be avoided during and for a period after therapy because it can promote conversion to a longer-lived teratogenic metabolite, and blood donation is contraindicated.
Monitoring
Monitor liver function and fasting lipids regularly, alongside pregnancy testing where applicable.
Counselling the patient
- Effective contraception is essential during treatment and for the full advised period after stopping.
- Avoid alcohol and do not donate blood during and after treatment as directed.
- Expect dry lips, skin and eyes, and report visual disturbance or persistent headache.
Evidence & guidelines
Acitretin is an established systemic option for severe psoriasis, and MHRA pregnancy prevention requirements for oral retinoids govern its prescribing.
Reference: BAD Psoriasis Guidelines; MHRA Retinoid Pregnancy Prevention Programme; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD